Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate

被引:9
作者
Yildirim, Berna Akkus [1 ]
Onal, Cem [1 ]
Kose, Fatih [2 ]
Oymak, Ezgi [3 ]
Sedef, Ali Murat [4 ]
Besen, Ali Ayberk [2 ]
Aksoy, Sercan [5 ]
Guler, Ozan Cem [1 ]
Sumbul, Ahmet Taner [2 ]
Muallaoglu, Sadik [6 ]
Mertsoylu, Huseyin [2 ]
Ozyigit, Gokhan [6 ]
机构
[1] Baskent Univ, Adana Dr Turgut Noyan Res & Treatment Ctr, Fac Med, Dept Radiat Oncol, TR-01120 Adana, Turkey
[2] Baskent Univ, Div Med Oncol, Fac Med, TR-01120 Adana, Turkey
[3] Iskenderun Gelisim Hosp, Div Radiat Oncol, Antakya, Turkey
[4] Adana City Hosp, Div Med Oncol, Adana, Turkey
[5] Hacettepe Univ, Div Med Oncol, Fac Med, Ankara, Turkey
[6] Hacettepe Univ, Dept Radiat Oncol, Fac Med, Ankara, Turkey
关键词
Prostate; Survival; Local recurrence; Hormonotherapy; Metastasis; INCREASED SURVIVAL; PLUS PREDNISONE; NEPHRECTOMY; ANTIGEN; MEN; IMMUNOTHERAPY; ENZALUTAMIDE; MITOXANTRONE; POPULATION; THERAPY;
D O I
10.1007/s00066-019-01429-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the potential benefit of curative radiotherapy (RT) to the primary tumor in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone. Materials and methods The clinical parameters of 106 mCRPC patients treated with abiraterone were retrospectively evaluated. Patients were either oligometastatic (<= 5 metastases) at diagnosis or became oligometastatic after the systemic treatment was analyzed. Local RT to the primary tumor and pelvic lymphatics was delivered in 44 patients (41%), and 62 patients (59%) did not have RT to the primary tumor. After propensity match analysis, a total of 92 patients were analyzed. Resultsn Median follow-up time was 14.2 months (range: 2.3-54.9 months). Median overall survival (OS) was higher in patients treated with local RT to the primary tumor than in those treated without local RT with borderline significance (24.1 vs. 21.4 months; p=0.08). Local RT to the prostate and pelvic lymphatics significantly diminished the local recurrence rate (16 patients, 31% vs. 2 patients, 5%; p=0.003). In multivariate analysis, the prostate specific antigen (PSA) response >= 50% of the baseline obtained 3 weeks after abiraterone therapy was the only significant prognostic factor for better OS and progression-free survival (PFS). Patients treated with primary RT to the prostate had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT. Conclusions Local prostate RT significantly improved OS and local control in mCRPC patients treated with abiraterone. The patients treated with primary RT had significantly less progression under abiraterone and a longer abiraterone period than those treated without local prostate RT.
引用
收藏
页码:872 / 881
页数:10
相关论文
共 35 条
  • [1] Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer
    Aizawa, Rihito
    Takayama, Kenji
    Nakamura, Kiyonao
    Inoue, Takahiro
    Kobayashi, Takashi
    Akamatsu, Shusuke
    Yamasaki, Toshinari
    Ogawa, Osamu
    Mizowaki, Takashi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) : 749 - 756
  • [2] Ten-Year Outcomes of High-Dose, Intensity-Modulated Radiotherapy for Localized Prostate Cancer
    Alicikus, Zumre A.
    Yamada, Yoshiya
    Zhang, Zhigang
    Pei, Xin
    Hunt, Margie
    Kollmeier, Marisa
    Cox, Brett
    Zelefsky, Michael J.
    [J]. CANCER, 2011, 117 (07) : 1429 - 1437
  • [3] Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
  • [4] May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?
    Botticella, Angela
    Guarneri, Alessia
    Filippi, Andrea Riccardo
    Levra, Niccolo Giaj
    Munoz, Fernando
    Ragona, Riccardo
    Gontero, Paolo
    Ricardi, Umberto
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (11) : 1955 - 1960
  • [5] Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
    Crawford, E. David
    Higano, Celestia S.
    Shore, Neal D.
    Hussain, Maha
    Petrylak, Daniel P.
    [J]. JOURNAL OF UROLOGY, 2015, 194 (06) : 1537 - 1547
  • [6] Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era
    Culp, Stephen H.
    Karam, Jose A.
    Wood, Christopher G.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 561 - 568
  • [7] Abiraterone and Increased Survival in Metastatic Prostate Cancer
    De Bono, Johann S.
    Logothetis, Christopher J.
    Molina, Arturo
    Fizazi, Karim
    North, Scott
    Chu, Luis
    Chi, Kim N.
    Jones, Robert J.
    Goodman, Oscar B., Jr.
    Saad, Fred
    Staffurth, John N.
    Mainwaring, Paul
    Harland, Stephen
    Flaig, Thomas W.
    Hutson, Thomas E.
    Cheng, Tina
    Patterson, Helen
    Hainsworth, John D.
    Ryan, Charles J.
    Sternberg, Cora N.
    Ellard, Susan L.
    Flechon, Aude
    Saleh, Mansoor
    Scholz, Mark
    Efstathiou, Eleni
    Zivi, Andrea
    Bianchini, Diletta
    Loriot, Yohann
    Chieffo, Nicole
    Thian Kheoh
    Haqq, Christopher M.
    Scher, Howard I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) : 1995 - 2005
  • [8] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    de Bono, Johann Sebastian
    Oudard, Stephane
    Ozguroglu, Mustafa
    Hansen, Steinbjorn
    Machiels, Jean-Pascal
    Kocak, Ivo
    Gravis, Gwenaelle
    Bodrogi, Istvan
    Mackenzie, Mary J.
    Shen, Liji
    Roessner, Martin
    Gupta, Sunil
    Sartor, A. Oliver
    [J]. LANCET, 2010, 376 (9747) : 1147 - 1154
  • [9] Evidence-based standards for cancer pain management
    Dy, Sydney M.
    Asch, Steven M.
    Naeim, Arash
    Sanati, Homayoon
    Walling, Anne
    Lorenz, Karl A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (23) : 3879 - 3885
  • [10] The "seed and soil" hypothesis revisited
    Fidler, Isaiah J.
    Poste, George
    [J]. LANCET ONCOLOGY, 2008, 9 (08) : 808 - 808